Publiclisting.in
Your Comprehensive Guide to the Latest Market Offerings
Pramodini Medicare IPO: Complete Analysis, Dates, Financials, and Review
The healthcare and diagnostic sector in India has witnessed monumental growth over the past decade, driven by increasing awareness and the necessity for accurate medical testing. Emerging as a notable player in this segment, Pramodini Medicare Limited is all set to enter the public market with its Initial Public Offering (IPO). This blog post offers an in-depth, data-backed overview of the Pramodini Medicare IPO, encompassing crucial dates, financial health, valuation, and a strategic market review to help you make an informed financial decision.
About Pramodini Medicare Limited
Established in the year 2000, Pramodini Medicare Limited has solidified its position as a reliable diagnostic service provider across India. Leveraging modern technology, the company delivers a broad spectrum of diagnostic solutions spanning radiology, clinical laboratories, and nuclear medicine.
The company caters to a diverse clientele including government hospitals, private healthcare institutions, medical colleges, and individual patients. As of mid-2026, the firm successfully operates 16 diagnostic centers spread out across seven Indian states, supported by a dedicated workforce of over 160 employees.
Core Business Models:
- Public-Private Partnerships (PPP): Managing diagnostic facilities within government hospitals and medical educational institutions through long-term memorandums of understanding.
- Private-Private Partnerships: Setting up and running specialized diagnostic wings inside private hospital establishments.
- PSU Strategic Collaborations: Partnering with Public Sector Undertakings to manage diagnostic and imaging centers nationwide.
- Standalone Diagnostic Clinics: Operating fully independent diagnostic laboratories serving direct walk-in patients and localized clinics.
Pramodini Medicare IPO Details
This upcoming public issue is a combination of a fresh issue of shares and an Offer for Sale (OFS) from existing promoters. The SME IPO aims to raise capital primarily to bolster the company's infrastructure and technological capabilities.
| Particulars | Details |
|---|---|
| Issue Type | Book Built Issue |
| Total Issue Size | ₹69.04 Crores (58,51,200 shares) |
| Fresh Issue Component | ₹63.14 Crores |
| Offer For Sale (OFS) | ₹5.90 Crores (5,00,400 shares) |
| Price Band | ₹110 to ₹118 per equity share |
| Face Value | ₹10 per share |
| Listing Platform | NSE SME |
Important IPO Dates & Timeline
Tracking the timeline is vital for seamless application and fund management. Below is the scheduled trajectory from the opening date to the market listing.
Investment Lot Size Limits
To participate in this offering, retail and High Net-worth Individuals (HNIs) must adhere to the prescribed lot sizes. A single lot constitutes 1,200 shares.
| Investor Category | Minimum Lots | Total Shares | Investment Amount (at ₹118) |
|---|---|---|---|
| Retail Individual (Min/Max) | 2 Lots | 2,400 Shares | ₹2,83,200 |
| S-HNI (Min) | 3 Lots | 3,600 Shares | ₹4,24,800 |
| S-HNI (Max) | 7 Lots | 8,400 Shares | ₹9,91,200 |
| B-HNI (Min) | 8 Lots | 9,600 Shares | ₹11,32,800 |
Company Financial Performance
A closer look at the financial trajectory of Pramodini Medicare highlights an impressive upward trend. Between the financial years concluding March 31, 2025, and March 31, 2026, the company reported a stellar 64% surge in revenue, complemented by a 56% growth in Profit After Tax (PAT).
| Financial Metric (in ₹ Crores) | FY Ended Mar 31, 2024 | FY Ended Mar 31, 2025 | FY Ended Mar 31, 2026 |
|---|---|---|---|
| Total Assets | 48.78 | 56.45 | 93.62 |
| Total Income | 35.79 | 38.55 | 63.38 |
| Profit After Tax (PAT) | 7.14 | 11.14 | 17.38 |
| Net Worth | 24.75 | 35.77 | 53.15 |
| Total Borrowing | 11.96 | 10.81 | 17.85 |
Key Performance Indicators (KPIs) & Valuation
Evaluating the KPIs gives a clear picture of the management's efficiency in utilizing resources. The robust Return on Equity (ROE) and healthy margins signify operational excellence.
- ROE (Return on Equity): 39.08%
- ROCE (Return on Capital Employed): 34.66%
- Debt to Equity Ratio: 0.34 (indicates a highly manageable debt profile)
- PAT Margin: 27.90%
- Pre-IPO EPS: ₹10.41 | Post-IPO EPS: ₹7.88
- Post-IPO Price-to-Earnings (P/E) Ratio: Approx. 14.97x
- Market Capitalization at Upper Band: ₹260.14 Crores
Objectives of the IPO
The management plans to channel the net proceeds raised from the fresh issue into productive avenues to drive the next phase of corporate growth:
- Capital Expenditure (₹45.15 Crores): Procurement of advanced medical equipment for upgrading existing centers and establishing new diagnostic hubs.
- General Corporate Purposes: Utilizing the remaining funds for operational liquidity, identifying strategic inorganic acquisitions, and covering standard corporate expenses.
Promoter Holding & Anchor Investors
The company is promoted by Chalasani Kuldeep Kumar, Chalasani Kavitha, Chalasani Durga Aashritha, Chalasani Lalithakumar, and Sri Ram Medicare Pvt. Ltd. Prior to the public offering, the promoter group holds an 85.71% stake. Post-listing, their shareholding will dilute to a balanced 62.64%, allowing significant public participation.
Demonstrating institutional confidence, the company successfully raised ₹16.06 Crores from anchor investors on August 11, 2026, allocating a total of 13,60,800 shares with standard regulatory lock-in periods applied.
SWOT Analysis of Pramodini Medicare
Strengths
- Diverse business models (PPP, PSUs, Standalone).
- Consistent year-on-year financial and margin growth.
- Experienced leadership and robust IT infrastructure.
Weaknesses
- High capital dependency for purchasing imported medical equipment.
- Potential vulnerability to regional market disruptions in operational states.
Opportunities
- Growing awareness regarding preventive healthcare in Tier-II & Tier-III cities.
- Expansion potential through strategic inorganic acquisitions.
Threats
- Intense competition from organized diagnostic chains and local unorganized labs.
- Fast-paced technological obsolescence requiring frequent equipment upgrades.
General Market Review and Sentiment
Market Outlook: Operating in a highly fragmented yet rapidly expanding diagnostic sector, Pramodini Medicare has showcased stellar top-line and bottom-line growth over recent fiscals. The impressive margins and sound fundamental metrics make it a visually attractive business model.
However, market analysts note that sustaining such aggressive outperformance in a fiercely competitive environment could be challenging. The issue is considered aggressively priced, factoring in near-term future earnings. Therefore, market sentiment suggests that cash-surplus investors with a long-term investment horizon and an appetite for moderate risk may consider allocating funds to this offering.
Registrar and Lead Management Info
For application-related queries, allotment status, or demat account credits, investors can reach out to the official registrar:
- Registrar: Purva Sharegistry (India) Pvt. Ltd.
- Email Support: newissue@purvashare.com
- Book Running Lead Manager: Smart Horizon Capital Advisors Pvt. Ltd.
Conclusion
The Pramodini Medicare IPO opens doors for investors to buy into a technologically equipped, fast-growing diagnostic chain with a proven operational track record. While the company's financial metrics reflect high profitability and manageable debt, investors should carefully weigh the competitive nature of the healthcare sector and the current valuation multiples before committing capital. Proper due diligence and portfolio alignment are strongly recommended.
Disclaimer: The analysis and data provided above are for educational and informational purposes only. It does not constitute financial or investment advice. Investors should consult their certified financial advisors before making any investment decisions.